Exploring Cost-Effectiveness of the Comprehensive Geriatric Assessment in Geriatric Oncology: A Narrative Review

Abstract

The Comprehensive Geriatric Assessment (CGA) and the corresponding geriatric interventions are beneficial for community-dwelling older persons in terms of reduced mortality, disability, institutionalisation and healthcare utilisation. However, the value of CGA in the management of older cancer patients both in terms of clinical outcomes and in cost-effectiveness remains to be fully established, and CGA is still far from being routinely implemented in geriatric oncology. This narrative review aims to analyse the available evidence on the cost-effectiveness of CGA adopted in geriatric oncology, identify the relevant parameters used in the literature and provide recommendations for future research. The review was conducted using the PubMed and Cochrane databases, covering published studies without selection by the publication year. The extracted data were categorised according to the study design, participants and measures of cost-effectiveness, and the results are summarised to state the levels of evidence. The review conforms to the SANRA guidelines for quality assessment. Twenty-nine studies out of the thirty-seven assessed for eligibility met the inclusion criteria. Although there is a large heterogeneity, the overall evidence is consistent with the measurable benefits of CGA in terms of reducing the in-hospital length of stay and treatment toxicity, leaning toward a positive cost-effectiveness of the interventions and supporting CGA implementation in geriatric oncology clinical practice. More research employing full economic evaluations is needed to confirm this evidence and should focus on CGA implications both from patient-centred and healthcare system perspectives.

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?

“…In recent years, the concept of being elderly has changed from a purely chronological evaluation to a more complex one, which also considers the biological age and functional and social status of the subjects. In this regard, several scales have been developed that can assess specific aspects, including function, comorbidities, quality of life, cognition, and emotional state [ 31 ], and a comprehensive geriatric assessment on decision making and treatment allocation is usually included in the multidisciplinary evaluation of elderly NSCLC patients.…”

Older adults and the unique role of the radiation therapist: Future directions for improving geriatric oncology training and education

“…Further, it is arguable that the implementation of such a RTT role has the potential to be cost neutral and could potentially encompass specialisation in care of the older adult more broadly across the cancer care pathway [43] . Analyses to date lean toward a positive cost-effectiveness of geriatric focussed interventions in clinical practice in cancer [46] . We argue this would likely to translate into RO in terms of cost and staff resource savings via reduction of in-hospital admissions/length of stay, RT treatment toxicity and completion.…”

Geriatric assessment with management for older patients with cancer receiving radiotherapy: a cluster-randomised controlled pilot study

“…management of impairments identified by a systematic assessment of comorbidities, medications, nutritional status, physical and cognitive function, depressive symptoms, and social support [ 7 , 8 , 9 ]. Several randomised controlled trials (RCT), predominantly addressing older patients receiving cancer surgery or chemotherapy, have shown that GAM interventions may facilitate treatment completion, and reduce adverse events and the need for hospital services [ 10 , 11 ]. Benefits related to quality of life (QoL) and physical performance are more poorly documented [ 10 , 11 ].…”